Insiders

Stock News Buzz: Ionis Pharmaceuticals (NASDAQ: IONS)

Ionis Pharmaceuticals (NASDAQ: IONS) spotted trading -37.07% off 52-week high price. On the other end, the stock has been noted 19.81% away from the low price over the last 52-weeks. The stock changed -0.44% to recent value of $54.49. The stock transacted 943724 shares during most recent day however it has an average volume of 1031.55K shares. The company has 142.39M of outstanding shares and 127.76M shares were floated in the market.  

Ionis Pharmaceuticals (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced that Ionis’ Chairman and Chief Executive Officer, Stanley T. Crooke, M.D., Ph.D., is one of two scientists to be awarded the 2019 Massry Prize. Dr. Crooke, who founded Ionis 30 years ago to create a radically different drug discovery platform, was recognized by the Massry Foundation for his pioneering work to establish an entirely new chemical class of medicines, antisense oligonucleotides. Ionis’ antisense technology has created the life-changing medicines SPINRAZA®, TEGSEDI® and WAYLIVRA® and a pipeline of more than 40 first-in-class or best-in-class therapies focused on rare and common diseases.

“I am deeply honored to accept the Massry Prize. This award is positive affirmation of the perseverance and commitment that we at Ionis have to advancing science and to delivering transformative medicines to the patients who depend on us,” said Dr. Crooke.

The Meira and Shaul G. Massry Foundation established the Massry Prize in 1996 to recognize outstanding contributions to the biomedical sciences and the advancement of health. Founded by Dr. Shaul Massry, professor emeritus of medicine at the Keck School of Medicine of the University of Southern California, the nonprofit foundation promotes education and research in nephrology, physiology, and related fields. In addition to a substantial monetary award, prize laureates also participate in the Massry Lectures, held at the University of Southern California and the University of California-Los Angeles.

 Its earnings per share (EPS) expected to touch remained 139.20% for this year while earning per share for the next 5-years is expected to reach at 49.00%. IONS has a gross margin of 57.50% and an operating margin of 11.90% while its profit margin remained 50.00% for the last 12 months. 

 According to the most recent quarter its current ratio was 10 that represents company’s ability to meet its current financial obligations. The price moved ahead of -7.58% from the mean of 20 days, -13.08% from mean of 50 days SMA and performed -17.94% from mean of 200 days price. Company’s performance for the week was -5.43%, -11.04% for month and YTD performance remained 0.80%.

Leave a Reply

Your email address will not be published. Required fields are marked *